Tempest Therapeutics Advances CAR-T Pipeline with China Collaboration
Event summary
- Tempest Therapeutics partnered with Senlang Biotechnology to advance TPST-4003, a CD7-targeted in vivo CAR-T, with first patient dosing expected in Q4 2026.
- TPST-2003 showed 100% complete response rate in 15 CAR-T-naïve patients across two clinical trials for relapsed/refractory multiple myeloma and POEMS syndrome.
- Tempest appointed Drake Richey and John Yee, MD, MPH, to its Board of Directors.
- The company ended Q2 2026 with $0.8 million in cash, down from $7.7 million at the end of 2025.
The big picture
Tempest Therapeutics is positioning itself as a leader in next-generation in vivo CAR-T therapies, leveraging strategic partnerships to advance its pipeline. The collaboration with Senlang Biotechnology underscores the company’s focus on expanding into the Chinese market, while positive clinical results for TPST-2003 reinforce its potential in treating relapsed/refractory multiple myeloma and POEMS syndrome. However, Tempest’s financial stability remains a critical factor as it navigates the capital-intensive biotech landscape.
What we're watching
- Clinical Progress
- The pace at which TPST-4003 advances through its investigator-initiated trial in China will signal the effectiveness of Tempest’s CD7-targeted mRNA/LNP delivery approach.
- Financial Stability
- Whether Tempest can secure additional funding to sustain operations, given its significant cash burn and limited reserves.
- Board Impact
- How the new board members influence strategic decisions, particularly in expanding Tempest’s outreach and partnering efforts in China.
Related topics